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Abstract
Background: Cellular redox state is important to cell growth and death. The growth of tumor
cells may be modulated by intracellular reduced glutathione/oxidized glutathione (GSH/GSSG). The
present study aims to investigate the effects of ginsenosides Re and Rg3 on cellular redox state and
cell proliferation in C6 glioma cells.
Methods: Cultured C6 glioma cells were exposed to various concentrations of either Rg3 or Re
for 24 hours. Cell growth and death were measured by the BrdU incorporation assay and the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay respectively. Cellular
redox state was determined by free radical production using flow cytometry and GSH/GSSG using
spectrofluorometry.
Results: At a sub-lethal concentration, Re suppressed cell proliferation with a significant decrease
in BrdU incorporation. Re did not increase reactive oxygen species (ROS) production but
increased GSH/GSSG via increased activity of gamma glutamylcystenyl synthase (γ-GCS). In
contrast, Rg3 increased free radical production and reduced GSH/GSSG. The effects of Rg3 were
probably due to increased activity of glutathione peroxidase (GPx).
Conclusion: Re and Rg3 alter cellular redox state of C6 glioma cells in opposite directions.
Changes in cellular redox state induced by Re and Rg3 are correlated with the proliferation rates
of C6 glioma cells.
Background
Cellular redox state can be monitored by intracellular
thiol levels, among which the ratio of reduced glutathione
(GSH) and oxidized glutathione (GSSG) is the most use-
ful [1,2]. In the presence of free radicals, mainly H2O2,
GSH acts as electron donor and is oxidized into GSSG by
glutathione peroxidase (GPx). The GSSG generated is later
converted back to GSH by glutathione reductase (GR) in
which reduced nicotinamide adenine dinucleotide phos-
phate (NADPH) is the hydrogen donor. In living tissues,
the level of glutathione is ranged 5–10 mM. In cultured
cells, the level of intracellular glutathione is several folds
higher than the level of total adenosine nucleotides [3].
Under stable conditions, cells maintain a constant ratio of
GSH/GSSG [1,4,5]. Excessive reactive oxygen species
(ROS) decreases the GSH/GSSG ratio [6]. The GSH/GSSG
ratio is increased by the addition of N-acetylcysteine
(NAC, a cysteine analogue) [7] or by improved enzymes
for glutathione synthesis [8]. Antioxidants or molecules
that increase the GSH/GSSG ratio suppress cell prolifera-
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tion [9-14], while oxidative stress increases cell prolifera-
tion and leads to cell death [2,15-19]. Cellular redox state
also affects cellular signaling pathways, gene expression
and enzymes associated with cell cycle progression
[2,6,11,12,15,16,18,19]. Conour et al. identified 92 can-
didate proteins involved in cell cycle progression that are
redox sensitive [20]. Growth and metastasis of tumor cells
may also be regulated by intracellular redox state
[2,17,21,22].
Ginseng (Panax ginseng, Renshen) is a popular Chinese
herbal medicine known for its wide spectrum of pharma-
cological actions [23]. Ginseng is composed of a series of
saponins known as ginsenosides which are derivatives of
triterpene dammarane. There are two categories of ginse-
nosides, namely protopanaxadiol (PPD, e.g. Ra, Rb, Rc,
Rd, Rg3, Rh2) and protopanaxatriol (PPT, e.g. Re, Rf, Rg1,
Rg2, Rh1). Each gensenoside is characteristic in its sugar
moiety position on dammarane. Some ginsenosides mod-
ulate cardiovascular and neurological functions [24],
whereas others act as antioxidants [25-29] to prevent can-
cer [30-32], protect against chemically induced tissues
damage [33-36] and delay ageing [25]. Ginsenoside Re
has anti-oxidative abilities apart from its immunomodu-
latory, antihyperlipidemic and neuroprotective activities.
In cardiomyocytes, pretreatment with Re significantly
attenuates H2O2 induced free radical production and pro-
tect cell death [37]. Rg3 acts as a prooxidant to accelerate
2,2'-azobis (2-amidinopropane) hydrochloride (AAPH)
induced haemolysis in human erythrocytes [26]. Rg3 is
anti-angiogenic and anticancer through inducing apopto-
sis [30,38].
Ginsenosides are active components in ginseng which has
anticancer properties [23,32,39-41]. The present study
investigates how Re and Rg3 suppress the growth of C6
glioma cells. The C6 glioma cell is a model for studying a
form of malignant brain tumor glioblastoma multiform
[42]. The study also investigates the mechanisms through
which ginsenosides Re and Rg3 modulate the levels of oxi-
dized and reduced glutathione, and ROS production
Methods
Materials
Cell culture media and all reagents for biochemical assays
were purchased from Sigma Chemical (MO, USA). Per-
chloric acid (PCA) and potassium hydroxide were pur-
chased from Fisher Scientific (NJ, USA). Antibiotics were
purchased from Life Technologies (NY, USA). Fetal
bovine serum (FBS) and 6-carboxy-2,7-dichlorodihy-
drofluorescein diacetate (H2DCFDA) were purchased
from Invitrogen (Scotland, UK) and Molecular Probes
(NJ, USA) respectively.
Ginsenosides Re and Rg3 (purity>99%) were obtained
from International laboratory (USA). The identities of
ginsenosdies were confirmed by high-performance liquid
chromatography (HPLC) and electrospray ionization –
mass spectrometry (ESI-MS). The Rg3, a 20(S) isoform,
and the Re were 784 Daltons and 946 Daltons of molecu-
lar weight respectively (Figure 1). In this study, the con-
centration of ginsenosides was based on nominal weight.
The ginsenosides were dissolved in dimethyl sulfoxide
(DMSO), filtered (0.2 μm membrane) and added to the
culture media to achieve various final concentrations.
Buthionine-(S,  R)-sulfoximine (BSO), an inhibitor of
gamma glutamylcystenyl synthase (γ-GCS), was dissolved
in phosphate buffered saline (PBS) and sterilized through
a 0.2 μm membrane. Cultured C6 glioma cells (ATCC no
CCL-107) were purchased from the American Type Cul-
ture Collection (USA).
Chemical structures of ginsenosides Re and Rg3 (adapted from chemBlink http://www.chemblink.com/) Figure 1
Chemical structures of ginsenosides Re and Rg3 (adapted from chemBlink http://www.chemblink.com/).
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Cell culture
The cells were maintained in the F-12 medium supple-
mented with 10% FBS (tested for lipopolysaccharide) and
0.5% antibiotics (amphotericin B and penicillin-strepto-
mycin) in a humidifier under 95% air and 5% CO2 at
37°C.
Treatment of cells
Cells were sub-cultured into 6-well plates until conflu-
ence. The incubation media were then removed and
replaced with those containing the required concentration
of Rg3 or Re. The concentration of DMSO in each well was
kept at 0.5%, which did not affect intracellular glutath-
ione level and GSH/GSSG. Cells were treated with 100 μM
BSO for 24 hours for the study of cell response in the
absence of GSH.
Analysis of cell viability
The viability of C6 glioma cells treated with Re and Rg3
was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Briefly, cells
were cultured in 96-well plates and treated with various
concentrations (0–800 μg/ml) of Re or Rg3. After incuba-
tion, cells were washed twice with PBS. A medium (100
μl) containing 500 μg/ml MTT was added to each well.
The medium was removed after 3 hours of incubation and
DMSO (100 μl) was added to dissolve the formazan crys-
tals. Light absorbance at 595 nm was measured with a
microplate reader (Tecan Infinite F200, Germany). Cell
viability was the optical density ratio of a treated culture
over an untreated control.
Cell proliferation assay
The effects of either Re or Rg3 on cell proliferation were
determined by the BrdU cell proliferation kit (Calbio-
chem, Germany). Cells were cultured in 96-well plates.
Upon confluence, they were incubated with either Re or
Rg3 of various concentrations for 24 hours. BrdU was
added to the medium 20 hours before the end of incuba-
tion. The amount of BrdU incorporated into cells was
determined by binding BrdU to mouse anti-BrdU anti-
body conjugated with horseradish peroxidase. Tetra-
methylbenzidine, the substrate of horseradish peroxidase,
was later added. The color product of the enzymatic reac-
tion was measured in a microplate reader (Tecan Infinite
F200, Germany) at 450–540 nm.
Analysis of intracellular glutathione metabolism
Intracellular glutathione metabolism is reflected by the
interplay of GSH, GSSG, GPx, GR and γ-GCS. Cells were
incubated for 24 hours before intracellular metabolites
were extracted by 0.3 M PCA containing 1 mM ethylene-
diamine-tetraacetic acid (EDTA) with a previously
described method [43]. The levels of GSH and GSSG were
determined with spectrofluorometry [3]. For enzyme
assays, cells were washed twice with pre-warmed PBS and
extracted with a protein extraction kit (EMB Biosciences,
Calbiochem, USA) with a previously described method
[8].
Analysis of ROS production by flow cytometry
Intracellular production of ROS was evaluated with
H2DCFDA which is converted to a fluorescence product
dichlorodihydrofluoroscine (DCF) when treated with
H2O2. Cells were treated for 24 hours with either 100 μg/
ml of BSO or 200 μg/ml of Re. Thirty minutes before the
end of experiment, H2DCFDA was added (final concen-
tration 10 μM). The cells were then trypsinized, centri-
fuged, re-suspended in PBS and passed through the
FACScan flow cytometer (Becton Dickinson, U.S.A.). Flu-
orescence intensities of DCF were measured by excitation
wavelength of 488 nm and emission wavelength of 620
nm. In each sample, approximately 10000 cells were ana-
lyzed by the CellQuest software (Becton Dickinson,
U.S.A.).
Data analysis
Cellular redox state was determined by the ratio of GSH/
GSSG. Each experiment was repeated 3–8 times. The
means and standard deviations were calculated. The dif-
ferences between samples were evaluated by the one way
analysis of variance (ANOVA), followed by tests for differ-
ences between groups by a post-hoc method (Dunnett C)
without an assumption of equal variance between groups
(SPSS version 14). The differences with P < 0.05 were con-
sidered statistically significant.
Results
Selection of concentrations of Re and Rg3 for the study of 
cell proliferation
A 24 and 48 hour dose-response study was conducted.
Cells were treated with various concentrations (0–800 μg/
ml) of Re and Rg3. There was a significant reduction (P <
0.01) in cell viability upon treatment with 100 μg/ml of
Rg3 for 24 hours (Figure 2). At 48 hours, a significant dif-
ference (P < 0.01) in cell viability was observed when Rg3
concentration was 50 μg/ml. In contrast, there was no sig-
nificant change in cell viability after treatment with Re for
24 hours. At high concentrations (400 and 800 μg/ml),
cell viability decreased 20% after 48 hours.
A decrease in cell proliferation was also demonstrated by
decreased BrdU incorporation. While cell viability did not
decrease (Figure 2a) after treatment with low concentra-
tions of Re (50–200 μg/ml), BrdU incorporation (Figure
3) decreased 20% (P < 0.01). In contrast, Rg3 did not
decrease BrdU incorporation at concentrations below 200
μg/ml at which cell viability significantly decreased (P <
0.05).Chinese Medicine 2008, 3:8 http://www.cmjournal.org/content/3/1/8
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Glutathione metabolism
The resting level of GSH is three folds higher than that of
GSSG. The GSH/GSSG ratio ranges from 2 (in tumor cells)
to >40 (in normal cells) [44]. The GSH/GSSG ratio may be
altered by either toxicants [3] or antioxidants [45]. Re
treatment increased GSH but not GSSG (Figure 4a), while
Rg3 increased GSSG (Figure 4b) but not GSH. Rg3 treat-
ment decreased the GSH/GSSG ratio, while Re treatment
increased it (Figure 5). A decrease in the GSH/GSSG ratio
after treatment with Rg3 indicated oxidative stress. ROS
production was increased after treatment with Rg3 (Figure
6). Rg3, which decreased the GSH/GSSG ratio at 200 μg/
ml, also significantly increased ROS generation (Figure 6).
The results show that Rg3 and Re treatments changed the
intracellular GSH/GSSG ratio in opposite directions.
Re treatment did not significantly change the activity of
either GPx or GR (Figure 7a) but increased (P < 0.05) the
activity of γ-GCS, which is the rate limiting enzyme for
GSH synthesis (Figure 8). Rg3 significantly increased (P <
0.05) GPx without changing GR (Figure 7b) or γ-GCS
(Figure 8).
Suppreession of γ-GCS activity by BSO reverses Re induced 
changes
To further confirm that Re acts by changing γ-GCS activity,
treatment of cells with BSO, an inhibitor of γ-GCS which
could significantly lowered (P<0.01) the GSH/GSSG ratio
(Figure 9) and increased (P<0.05) cellular ROS produc-
tion (Figure 6), was able to reverse the Re induced change
in both GSH/GSSG (Figure 9) and BrdU incorporation
(Figure 10).
Discussion
The present study showed that both Re and Rg3 affected
the survival of C6 glioma cells. While Re suppressed the
growth of C6 glioma cells at low concentrations, Rg3
caused death of C6 glioma cells via oxidative stress. Fur-
thermore, we demonstrated that the action of Re was cor-
related with an increase in the intracellular GSH level,
thereby raising the GSH/GSSG ratio. BSO (an inhibitor of
γ-GCS) treatment reversed the GSH/GSSG rise induced by
Re (Figure 9) and decreased BrdU incorporation in the
presence of Re (Figure 10).
γ-GCS is the rate limiting enzyme in glutathione synthesis.
The enzyme and its gene expression may be modulated by
a number of factors. For example, an increase in the γ-GCS
activity may be stimulated by oxidative metabolites. Shi et
Changes in cell viability of cells treated with (a) Re or (b) Rg3  for 24 and 48 hours Figure 2
Changes in cell viability of cells treated with (a) Re or 
(b) Rg3 for 24 and 48 hours. Each value represents the 
mean and standard deviation of 8 replicates. **: statistically 
significant (P < 0.01)
(a) 
BrdU incorporation assay in C6 glioma cells treated with var- ious concentrations of Re and Rg3 for 24 hours Figure 3
BrdU incorporation assay in C6 glioma cells treated 
with various concentrations of Re and Rg3 for 24 
hours. Each value represents the mean and standard devia-
tion of 8 replicates. *: statistically significant (P < 0.05). **: 
statistically significant (P < 0.01).Chinese Medicine 2008, 3:8 http://www.cmjournal.org/content/3/1/8
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al. showed that the heavy subunit mRNA level and subse-
quent enzyme activity increased in response to 2,3-
dimethoxy-1,4-napthoquinone (DMNQ) through tran-
scriptional activation of γ-GCS [46]. Our previous studies
showed that the production of quinone metabolite of
benzo [a]pyrene activated γ-GCS [8]. However, no such
quinone metabolites were detected in the metabolism of
Re in biological tissues. Furthermore, the present study
showed that Re treatment suppressed free radical produc-
tion (Figure 6), which did not support the free radical pro-
duction hypothesis in γ-GCS activation. Another study
showed that PC12 cells' tolerance of 7-hydroxycholesterol
and 15-deoxy-12,13- prostaglandin J2 was achieved via
up-regulation of cellular glutathione by γ-GCS transcrip-
tion [47]. Such feedback activation may be an underlying
cause of cellular adaptation to oxidative stress. Therefore,
similar adaptive response may take place in C6 glioma
cells following Re treatment.
Changes in the intracellular ROS level indicated by the fluo- rescence intensity (FLH-1) in C6 glioma cells treated with Re  (200 μg/ml), Rg3 (200 μg/ml) or BSO (100 μM) for 24 hours Figure 6
Changes in the intracellular ROS level indicated by 
the fluorescence intensity (FLH-1) in C6 glioma cells 
treated with Re (200 μg/ml), Rg3 (200 μg/ml) or BSO 
(100 μM) for 24 hours. The cytogram represents three 
independent experiments. The x-axis and y-axis denote fluo-
rescence intensity and cell count respectively.
 
Change in the GSH/GSSH ratio of C6 glioma cells treated  with Re and Rg3 for 24 hours Figure 5
Change in the GSH/GSSH ratio of C6 glioma cells 
treated with Re and Rg3 for 24 hours. Each value repre-
sents the mean and standard deviation of 4 replicates. *: sta-
tistically significant (P < 0.05). **: statistically significant (P < 
0.01).
Changes in the GSH and GSSG levels upon treatment with  (a) Re or (b) Rg3 for 24 hours Figure 4
Changes in the GSH and GSSG levels upon treat-
ment with (a) Re or (b) Rg3 for 24 hours. Each value 
represents the mean and standard deviation of 4 replicates. *: 
statistically significant (P < 0.05). **: statistically significant (P 
< 0.01).Chinese Medicine 2008, 3:8 http://www.cmjournal.org/content/3/1/8
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A number of factors must be considered before using Re
to treat brain tumor. Firstly, Re suppresses cell prolifera-
tion at a low rate. At a low concentration of 50 μg/ml, Re
was effective in suppressing cell proliferation (Figure 3).
However, there was only a 10% decrease in BrdU uptake
after 24 hours (Figure 2a), and only a 20% decrease in cell
viability after 48 hours. Secondly, Re is metabolized by
intestinal flora via deglycosylation and fatty acid esterifi-
cation [48], which may limit the application of Re given
per oral. Finally, it is not clear whether normal astrocytes
respond similarly to Re. In current anticancer strategies,
both normal and tumor cells are affected. Menon et al.
demonstrated that exposure of both nonmalignant
human breast epithelial (MCF-10A) and breast cancer
cells (MCF-7 and MDA-MB-231) to NAC decreased the
oxidation of a prooxidant-sensitive dye in MCF-10A cells,
but not in MCF-7 and MDA-MB-231 cells, suggesting that
malignant and non-malignant cells may have different
responses to oxidative stress [17]. We will further investi-
gate whether C6 glioma cells and normal astrocytes
respond differently to Re treatment.
Conclusion
Re suppresses the growth and proliferation of C6 glioma
cells and increases the cellular GSH/GSSG ratio by
enhancing the γ-GCS activity, suppressing ROS generation
and reducing cell proliferation rate. Rg3 causes cell death
via oxidative stress. While both Re and Rg3 eliminate the
growth and proliferation of C6 glioma cells, they modu-
late cellular redox state in opposite directions. Yue et al.
suggest that ginseng or selected ginsenosides modulate
cellular function via specific intracellular receptors in a
way that may reflect the Ying/Yang actions of ginseng
[49]. The opposite actions in modulating cellular redox
Changes in the γ-GCS activity of C6 glioma cells treated with  Re and Rg3 for 24 hours Figure 8
Changes in the γ-GCS activity of C6 glioma cells 
treated with Re and Rg3 for 24 hours. Each value repre-
sents the mean and standard deviation of 4 replicates. *: sta-
tistically significant (P < 0.05).
Changes in the GR and GPx activities of C6 glioma cells  treated with (a) Re and (b) Rg3 for 24 hours Figure 7
Changes in the GR and GPx activities of C6 glioma 
cells treated with (a) Re and (b) Rg3 for 24 hours. 
Each value represents the mean and standard deviation of 4 
replicates. *: statistcally significant (P < 0.05).Chinese Medicine 2008, 3:8 http://www.cmjournal.org/content/3/1/8
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state by Re and Rg3 may be another example of the Ying/
Yang actions of ginseng.
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